A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma.

Trial Profile

A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 06 Jun 2012 Additional location (Turkey) added as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 22 Dec 2011 Planned end date changed from 1 Oct 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top